Optimi Health Upgrades Trading to the OTCQX Best Market

Rhea-AI Summary

Optimi Health Corp. (CSE: OPTI, OTCQX: OPTHF) has upgraded its common shares to the OTCQX Best Market, enhancing visibility and accessibility for U.S. investors. This upgrade signifies an important milestone for the company, which focuses on developing functional and psychedelic mushroom products for health and wellness. The OTCQX is reserved for established companies meeting high financial standards and best corporate governance practices. Optimi continues its Canadian listing under the symbol OPTI.

Positive

• Optimi upgraded to OTCQX Best Market, increasing visibility to U.S. investors.
• The company meets high financial standards and governance practices required for OTCQX.
• Focus on functional and psychedelic mushroom products positions Optimi in a growing market.

Negative

• None.

VANCOUVER, British Columbia, March 01, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce the upgrade of its common shares to the OTCQX Best Market.

The OTCQX Best Market represents the highest tier of OTC Markets, which operates markets on which over 11,000 U.S. and global securities trade. Upgrading to the OTCQX Market is an important milestone for Optimi Health Corp., as it provides transparent trading, visibility, and accessibility for its U.S. investors. The OTCQX is for established, investor-focused U.S. and international companies. To qualify for the OTCQX market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, be current in their disclosure, and have a professional third-party sponsor introduction.

Optimi Health Corp. begins trading today on OTCQX under the symbol “OPTHF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"This is an important milestone for Optimi as we look to increase our presence in the capital markets. The OTCQX Best Market is the highest market tier of OTC Markets and can enhance the Company's visibility to U.S. investors," said Bill Ciprick, Chief Executive Officer of Optimi. "We believe this is an opportunistic time for all current and future investors to support the Company during this stage of growth and commercialization and look forward to begin trading on the OTCQX."

There will be no change to Optimi's Canadian listing as the Company's common shares will continue to trade on the Canadian Securities Exchange under the symbol OPTI.

On Behalf of the Board of Directors,

Bill Ciprick
Chief Executive Officer
Optimi Health Corp.

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION SEE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, "forward‐looking statements") that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements" and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

FAQ

What does the upgrade to OTCQX Best Market mean for Optimi Health Corp. (OPTHF)?

The upgrade to OTCQX Best Market enhances visibility and trading accessibility for U.S. investors, indicating financial stability and compliance with U.S. securities laws.

When did Optimi Health Corp. start trading on the OTCQX under the symbol OPTHF?

Optimi Health Corp. began trading on the OTCQX under the symbol OPTHF on March 1, 2022.

How does the OTCQX upgrade affect investors in Optimi Health Corp. (OPTHF)?

The OTCQX upgrade provides a more transparent trading environment, potentially attracting more investors and increasing stock liquidity.

Is there any change to Optimi’s Canadian listing after the OTCQX upgrade?

No, Optimi’s common shares will continue to trade on the Canadian Securities Exchange under the symbol OPTI without any changes.